1. Home
  2. COCP vs NERV Comparison

COCP vs NERV Comparison

Compare COCP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$1.15

Market Cap

21.6M

Sector

Health Care

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$3.45

Market Cap

166.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COCP
NERV
Founded
2006
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
166.4M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
COCP
NERV
Price
$1.15
$3.45
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$6.00
★ $10.50
AVG Volume (30 Days)
47.9K
★ 132.1K
Earning Date
05-15-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 54.65
N/A
EPS
★ N/A
N/A
Revenue
$12,712,091.00
★ $41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.76
$2.06
52 Week High
$2.03
$12.46

Technical Indicators

Market Signals
Indicator
COCP
NERV
Relative Strength Index (RSI) 58.89 34.01
Support Level $1.14 N/A
Resistance Level $1.25 $4.73
Average True Range (ATR) 0.07 0.28
MACD -0.00 -0.07
Stochastic Oscillator 57.47 0.00

Price Performance

Historical Comparison
COCP
NERV

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: